

Accepted Manuscript

Caffeine and Incidence of Dyspnea in Patients Treated with Ticagrelor

Daniel Lindholm, Stefan James, Jonas Andersson, Oscar Ö. Braun, Susanne Heller, Peter Henriksson, Jörg Lauermann, Patrik Öhagen, Christoph Varenhorst



PII: S0002-8703(18)30054-1
DOI: doi:[10.1016/j.ahj.2018.02.011](https://doi.org/10.1016/j.ahj.2018.02.011)
Reference: YMHJ 5633

To appear in:

Received date: 22 November 2017
Accepted date: 14 February 2018

Please cite this article as: Daniel Lindholm, Stefan James, Jonas Andersson, Oscar Ö. Braun, Susanne Heller, Peter Henriksson, Jörg Lauermann, Patrik Öhagen, Christoph Varenhorst, Caffeine and Incidence of Dyspnea in Patients Treated with Ticagrelor. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. *Ymhj*(2018), doi:[10.1016/j.ahj.2018.02.011](https://doi.org/10.1016/j.ahj.2018.02.011)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Caffeine and Incidence of Dyspnea in Patients Treated with Ticagrelor

Daniel Lindholm(1,2), Stefan James(1,2), Jonas Andersson(3), Oscar Ö Braun(4), Susanne Heller(2), Peter Henriksson(5), Jörg Lauermaann(6), Patrik Öhagen(2), Christoph Varenhorst(1,7)

1. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
2. Uppsala Clinical Research Center, Uppsala, Sweden
3. Heartcenter, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
4. Department of Cardiology, Clinical Sciences, Faculty of Medicine, Lund University, Skåne University Hospital, Lund, Sweden
5. Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
6. Department of Internal Medicine, Division of Cardiology, Ryhov Hospital, Jönköping, Sweden
7. Pfizer, Stockholm, Sweden

RCT# NCT02311088

Conflicts of interest:

DL: Reports institutional research grants and consultant fees to the institution from AstraZeneca and institutional research grants from GlaxoSmithKline.

SJ: Reports institutional research grant, honoraria, and consultant/advisory board fee from AstraZeneca; institutional research grant and consultant/advisory board fee from Medtronic; institutional research grants and honoraria from The Medicines Company; and consultant/advisory board fees from Janssen and Bayer.

JA: Reports no conflicts of interest.

OÖB: Reports institutional research grants from AstraZeneca, lecture and advisory board fees from AstraZeneca, Amgen and Bayer and is on the Clinical Endpoint Committee for AstraZeneca.

SH: Reports no conflicts of interest.

PH: Reports no conflicts of interest.

JL: Reports no conflicts of interest.

PÖ: Reports no conflicts of interest.

CV: received at the time the research was performed institutional research grants from AstraZeneca and The Medicines Company, lecture and advisory board fees from AstraZeneca, The Medicines Company and Boeringer Ingelheim, lecture fees from Bristol Myers Squibb, Pfizer and CSL Behring, and was on the Clinical Endpoint Committee for Pfizer, Bristol Myers Squibb, Philips and AstraZeneca. After the time the research was conducted but before the manuscript was submitted CV reports being a Pfizer employee.

Corresponding author:

Daniel Lindholm
Uppsala Clinical Research Center
Dag Hammarskjölds väg 38
SE-75185 Uppsala
daniel.lindholm@ucr.uu.se

Download English Version:

<https://daneshyari.com/en/article/8650967>

Download Persian Version:

<https://daneshyari.com/article/8650967>

[Daneshyari.com](https://daneshyari.com)